VAXNEUVANCE 15 Pneumococcal Vaccine — Vax-Before-Travel

VAXNEUVANCE 15 Pneumococcal Vaccine

Fact checked by Robert Carlson, MD

Jan 12

3 min read

U.S. FDA Accepts for Priority Review the Biologics License Application for Investigational 15-valent Pneumococcal Vaccine

Merck investigational 15-valent pneumococcal conjugate vaccine prevents disease

older man driving a car

Fact checked by Danielle Reiter, RN

Oct 20

5 min read

15-Valent Pneumococcal Conjugate Vaccine Reports Positive Phase 3 Results

Merck V114 pneumococcal conjugate vaccine consists of 15 serotypes

seniors taking a walk hand in hand

Fact checked by Kelley Lu, PharmD

May 8

4 min read

15-valent Pneumococcal Conjugate Vaccine Reports Very Positive Phase 2 Results

Merck V114 is a 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease

happy healthy little girl with yellow glass frames on

Fact checked by Kelley Lu, PharmD

Jan 30

3 min read

15-Valent Pneumococcal Conjugate Vaccine Granted Breakthrough Status

Merck’s V114 pneumococcal conjugate vaccine receives FDA Breakthrough Therapy Designation

children hugging each other.

Fact checked by Robert Carlson, MD

Apr 18

4 min read

Phase 3 Studies on PCV-15 Launched

To prevent pneumococcal disease, get vaccinated

older couple looking thru binoculars